Cooperative Agreement U44NS111672

This $427,625 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the University of Washington aims to develop and optimize two novel blood-based biomarker assays to improve clinical diagnosis and differential diagnosis of Parkinson's disease (PD) and multiple system atrophy (MSA). The key products and services to be delivered under this 2-year grant include: Further development and optimization of a flow cytometry-based assay (APOGEE) to directly quantify...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...

This Project Grant award of $414,191 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research by Drexel University investigating the relationship between structural variations in alpha-synuclein (α-syn) protein fibrils and the development of distinct neurodegenerative synucleinopathies such as Lewy body dementia, Parkinson's disease, and multiple system atrophy....

This $2,192,716 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to understand the role of serine-129 phosphorylation in the aggregation and spreading of α-synuclein pathology associated with Parkinson's disease, dementia with Lewy bodies, and related synucleinopathies. The project leverages novel serine-129 phospho-deficient and...

Federal Grant Award Summary Lo Biosciences, Inc. received a $305,621 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded September 25, 2025, with a completion date of September 24, 2026. The company is developing and validating the P1, a proprietary home-based plasma self-collection microtube device that separates whole blood into laboratory-quality, cell-depleted liquid plasma at the point-of-draw using magnetic bead technology. The award supports...

The National Institute on Aging (NIA) awarded a $459,250 Project Grant (CFDA 93.866 - Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate and validate the use of dried blood spot (DBS) samples for measuring Alzheimer's disease (AD) biomarkers. The key objectives are to: 1) optimize fingerstick collection methods and validate assays for three key AD biomarkers (pTau217, GFAP, and NFL) in DBS samples; 2) establish if DBS...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to establish the role of alpha-synuclein-mediated membrane permeabilization in the spread of alpha-synuclein aggregates related to Parkinson's disease and related dementias. The $406,260 award to Purdue University will leverage fluorescence lifetime imaging microscopy...

Federal Project Grant Award Summary Helical Biosciences LLC received a $395,951 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award, dated September 19, 2025, with completion targeted for August 31, 2026, supports the commercial development and production of Lewy Fold Fibrils (LFFs)—amplified preparations of alpha-synuclein fibrils derived...

This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $320,143 to Mayo Clinic to assess the diagnostic and disease biomarker utility of blood plasma measures in patients with atypical Alzheimer's disease (AD). The 2-year project aims to determine if plasma biomarkers can differentiate atypical AD patients from healthy controls and other clinical syndromes, as well as evaluate if the plasma biomarkers correlate with clinical...